RXRX Logo

Recursion Pharmaceuticals, Inc. (RXRX) 

NASDAQ
Market Cap
$1.98B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
704 of 776
Rank in Industry
386 of 433

Largest Insider Buys in Sector

RXRX Stock Price History Chart

RXRX Stock Performance

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 …

Insider Activity of Recursion Pharmaceuticals, Inc.

Over the last 12 months, insiders at Recursion Pharmaceuticals, Inc. have bought $0 and sold $15.65M worth of Recursion Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Recursion Pharmaceuticals, Inc. have bought $66.24M and sold $20.94M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 66,822 shares for transaction amount of $522,354 was made by Mubadala Investment Co PJSC (10 percent owner) on 2023‑03‑02.

List of Insider Buy and Sell Transactions, Recursion Pharmaceuticals, Inc.

2024-10-29Saledirector
11,447
0.004%
$6.72$76,926-3.26%
2024-10-24SalePresident and COO
6,000
0.002%
$6.31$37,8550.00%
2024-10-15Saledirector
11,447
0.0038%
$6.67$76,326+0.15%
2024-10-09SaleChief Financial Officer
15,000
0.0047%
$6.36$95,375+8.46%
2024-10-08SaleChief Financial Officer
15,000
0.0047%
$6.32$94,757+3.34%
2024-10-03SaleChief Executive Officer
20,000
0.006%
$6.08$121,600+9.24%
2024-10-02SaleChief Executive Officer
20,000
0.0061%
$6.16$123,200+7.77%
2024-10-01Saledirector
11,447
0.0035%
$6.22$71,150+6.16%
2024-09-26SalePresident and COO
6,000
0.0022%
$7.00$42,005-2.79%
2024-09-17Saledirector
11,447
0.0042%
$6.84$78,333-1.92%
2024-09-11SaleChief Financial Officer
15,000
0.0054%
$6.32$94,730+2.92%
2024-09-10SaleChief Financial Officer
15,000
0.0053%
$6.17$92,499+4.91%
2024-09-05SaleChief Executive Officer
20,000
0.0072%
$6.14$122,800+6.81%
2024-09-04SaleChief Executive Officer
20,000
0.0072%
$6.04$120,800+7.87%
2024-09-03Saledirector
11,447
0.0043%
$6.27$71,718+8.24%
2024-08-29SalePresident and COO
6,000
0.0022%
$7.56$45,376-11.34%
2024-08-20Saledirector
11,447
0.0041%
$7.12$81,532-7.19%
2024-08-14SaleChief Financial Officer
15,000
0.0057%
$6.35$95,2520.00%
2024-08-13SaleChief Financial Officer
15,000
0.0057%
$6.35$95,1830.00%
2024-08-08SaleChief Executive Officer
20,000
0.0075%
$6.50$130,000+0.08%

Insider Historical Profitability

<0.0001%
Mubadala Investment Co PJSC10 percent owner
12985927
4.5694%
$6.97420+0.28%
Lux Ventures IV, L.P.10 percent owner
100000
0.0352%
$6.9710<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
ARK Investment Management LLC$245.14M9.0124.59M+19.04%+$39.21M0.85
Baillie Gifford Co$239.96M8.8224.07M-0.46%-$1.11M0.19
The Vanguard Group$159.67M5.8716.01M+2.23%+$3.49M<0.01
BlackRock$122.84M4.5112.32M-0.59%-$726,184.90<0.01
Kinnevik Ab Publ$103.74M3.8110.41M0%+$0100
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.